Mizuho Raises Gilead Sciences (NASDAQ:GILD) Price Target to $170.00

Gilead Sciences (NASDAQ:GILD) had its price objective boosted by Mizuho from $140.00 to $170.00 in a note issued to investors on Wednesday,MarketScreener reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price target suggests a potential upside of 12.49% from the company’s current price.

A number of other research analysts have also weighed in on GILD. Needham & Company LLC increased their price target on shares of Gilead Sciences from $140.00 to $170.00 and gave the stock a “buy” rating in a report on Wednesday, February 11th. Bank of America set a $162.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Wednesday, February 11th. TD Cowen boosted their price target on shares of Gilead Sciences from $145.00 to $160.00 and gave the company a “buy” rating in a research report on Wednesday, February 11th. UBS Group upped their price target on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Finally, Cantor Fitzgerald lifted their price objective on Gilead Sciences from $135.00 to $155.00 and gave the company an “overweight” rating in a research note on Wednesday, February 11th. Twenty-three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Gilead Sciences presently has an average rating of “Moderate Buy” and an average target price of $154.21.

Gilead Sciences Stock Down 1.1%

GILD stock opened at $151.12 on Wednesday. Gilead Sciences has a 52 week low of $93.37 and a 52 week high of $157.29. The business has a 50-day simple moving average of $132.85 and a 200 day simple moving average of $123.38. The company has a quick ratio of 1.31, a current ratio of 1.68 and a debt-to-equity ratio of 1.03. The company has a market cap of $187.49 billion, a PE ratio of 22.32, a price-to-earnings-growth ratio of 2.03 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The company had revenue of $7.93 billion during the quarter, compared to the consensus estimate of $7.68 billion. During the same period in the prior year, the business earned $1.90 earnings per share. The company’s revenue for the quarter was up 4.7% compared to the same quarter last year. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Sell-side analysts anticipate that Gilead Sciences will post 7.95 EPS for the current fiscal year.

Insider Transactions at Gilead Sciences

In other news, insider Johanna Mercier sold 28,000 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $154.44, for a total transaction of $4,324,320.00. Following the sale, the insider directly owned 120,288 shares of the company’s stock, valued at $18,577,278.72. This represents a 18.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Andrew D. Dickinson sold 3,000 shares of the stock in a transaction dated Tuesday, February 17th. The shares were sold at an average price of $154.43, for a total transaction of $463,290.00. Following the completion of the transaction, the chief financial officer directly owned 167,779 shares of the company’s stock, valued at approximately $25,910,110.97. The trade was a 1.76% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 319,891 shares of company stock valued at $45,091,556. 0.27% of the stock is owned by company insiders.

Institutional Investors Weigh In On Gilead Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in GILD. Csenge Advisory Group lifted its stake in Gilead Sciences by 319.0% during the third quarter. Csenge Advisory Group now owns 21,394 shares of the biopharmaceutical company’s stock worth $2,375,000 after purchasing an additional 16,288 shares in the last quarter. Cookson Peirce & Co. Inc. raised its holdings in shares of Gilead Sciences by 249.1% in the 3rd quarter. Cookson Peirce & Co. Inc. now owns 10,045 shares of the biopharmaceutical company’s stock valued at $1,115,000 after buying an additional 7,168 shares during the period. Railway Pension Investments Ltd boosted its holdings in Gilead Sciences by 3.1% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,415,665 shares of the biopharmaceutical company’s stock valued at $157,139,000 after acquiring an additional 42,200 shares during the period. TriaGen Wealth Management LLC acquired a new position in Gilead Sciences in the 3rd quarter valued at about $1,274,000. Finally, iA Global Asset Management Inc. grew its position in Gilead Sciences by 11.6% in the 3rd quarter. iA Global Asset Management Inc. now owns 221,890 shares of the biopharmaceutical company’s stock valued at $24,630,000 after acquiring an additional 23,046 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Key Stories Impacting Gilead Sciences

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Rothschild & Co Redburn raised its price target to $170 and kept a Buy rating, reinforcing upside expectations tied to Gilead’s core franchises and supporting potential inflows. Rothschild PT Raise
• Positive Sentiment: Mizuho also lifted its target to $170 and maintained an Outperform rating — another analyst upgrade adding to buy-side momentum. Mizuho PT Raise
• Positive Sentiment: Q4 results showed an EPS beat and revenue beat, and management set FY‑2026 guidance at $8.45–$8.85 — this reinforces the earnings narrative (HIV franchise strength and durable cash flow) that underpins analyst optimism. Post-earnings Analyst Coverage
• Neutral Sentiment: Maxim Group reiterated a Hold rating, noting much of the HIV growth may be priced in and diversification remains limited — a cautious view that tempers aggressive upside. Maxim / Hold
• Neutral Sentiment: Analyst Q&A and feature pieces (including performance retrospectives) are providing context for investors but are mixed in directional impact — useful for positioning but unlikely to move price materially alone. Analyst Q&A
• Negative Sentiment: Insider selling: CFO Andrew Dickinson sold 3,000 shares at ~ $154.43 (Form 4 filing). Leadership sales often add near‑term selling pressure or raise governance questions for some investors. CFO Form 4
• Negative Sentiment: Significant insider sale: Johanna Mercier sold 28,000 shares at ~ $154.44 (an ~18.9% reduction in her holding), a larger single insider transaction that can weigh on investor confidence. Mercier Form 4

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.